04.21.14
Russia's Federal Service on Surveillance in Healthcare (Roszdravnadzor) has granted Zynex Inc. approval to market its NeuroMove stroke recovery device and NexWave electrotherapy product in that country.
The NexWave is an electrotherapy treatment device capable of delivering three modalities of stimulation: traditional TENS, interferential and neuromuscular electrical stimulation. The combined modalities of the NexWave provide various pain and muscle rehabilitation therapies through one device. The device was cleared by the U.S. Food and Drug Administration in 2011.
The NeuroMove device increases the functionality of many stroke victims by teaching the healthy parts of the brain to compensate for damaged areas. The NeuroMove, which is significantly more sensitive than most diagnostic equipment, monitors muscle activity and selects signals from the brain indicating that the patient is attempting to move a certain muscle. It then introduces the actual movement through electrical stimulation. Eventually the connection between the brain and muscle can often be reestablished. The NeuroMove also can be used to treat spinal cord injuries.
NeuroMove landed a five-year distribution deal with DIH Medical Technologies in China after receiving Chinese approval last fall. The deal calls for a minimum purchase commitment of $750,000 in the first year and $4.6 million in sales over the length of the contract.
Founded in 1996, Zynex operates under five primary business segments: Zynex Medical, Zynex NeuroDiagnostics, Zynex Monitoring Solutions, Zynex International and Zynex Billing and Consulting. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices for electrotherapy, used for pain management and rehabilitation. Zynex NeuroDiagnostics sells the company's proprietary NeuroMove device designed to help stroke and spinal cord injury patients and is currently expanding into markets for EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development and acquisitions. Zynex Monitoring Solutions, currently in the development stage, was established to develop and market medical devices for non-invasive cardiac monitoring.
Zynex is headquartered in Lone Tree, Colo.
The NexWave is an electrotherapy treatment device capable of delivering three modalities of stimulation: traditional TENS, interferential and neuromuscular electrical stimulation. The combined modalities of the NexWave provide various pain and muscle rehabilitation therapies through one device. The device was cleared by the U.S. Food and Drug Administration in 2011.
The NeuroMove device increases the functionality of many stroke victims by teaching the healthy parts of the brain to compensate for damaged areas. The NeuroMove, which is significantly more sensitive than most diagnostic equipment, monitors muscle activity and selects signals from the brain indicating that the patient is attempting to move a certain muscle. It then introduces the actual movement through electrical stimulation. Eventually the connection between the brain and muscle can often be reestablished. The NeuroMove also can be used to treat spinal cord injuries.
NeuroMove landed a five-year distribution deal with DIH Medical Technologies in China after receiving Chinese approval last fall. The deal calls for a minimum purchase commitment of $750,000 in the first year and $4.6 million in sales over the length of the contract.
Founded in 1996, Zynex operates under five primary business segments: Zynex Medical, Zynex NeuroDiagnostics, Zynex Monitoring Solutions, Zynex International and Zynex Billing and Consulting. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices for electrotherapy, used for pain management and rehabilitation. Zynex NeuroDiagnostics sells the company's proprietary NeuroMove device designed to help stroke and spinal cord injury patients and is currently expanding into markets for EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development and acquisitions. Zynex Monitoring Solutions, currently in the development stage, was established to develop and market medical devices for non-invasive cardiac monitoring.
Zynex is headquartered in Lone Tree, Colo.